Targeting Improved Outcomes in Atopic Dermatitis: Strategies for Achieving Personalized Treatment Goals

By clicking the continue button above, I certify that I have read the below CME/CE information.

A Series of CME-certified Activities

Welcome and Introductions
The Real Burden of Living with AD
Early Recognition of AD Drives Appropriate Treatment
New Approaches to Achieve New Treatment Goals
Q&A Session and Closing Remarks


 Lawrence F. Eichenfield, MD
 Professor of Dermatology and Pediatrics
 Vice Chair, Department of Dermatology
 Chief, Pediatric and Adolescent Dermatology
 Rady Children’s Hospital, San Diego
 University of California, San Diego School of Medicine
 San Diego, CA


 Jonathan M. Spergel, MD, PhD
 Professor of Pediatrics
 Chief, Allergy Section
 Stuart E. Starr Chair of Pediatrics
 Director of Center for Pediatric Eosinophilic Disease
 The Children's Hospital of Philadelphia
 Perelman School of Medicine at University of Pennsylvania
 Philadelphia, PA

For several decades, there have been no significant advances in the management of atopic dermatitis (AD). This lack of advancement has contributed to patient nonadherence with treatment regimens and progression of disease, and can be attributed, in part, to an insufficient understanding of the underlying pathophysiology of AD.

An improved understanding of AD pathogenesis has led to the development of new treatments that target the Th2-polarized immune system, which plays a key role in the symptoms of AD and progression of the atopic march to more severe skin disease and respiratory allergic conditions.

This CME activity will help allergists and dermatologists become more familiar with new treatment options for AD. Participants will also examine emerging biomarkers to tailor treatment selections based on specific biological signatures and predict and monitor therapeutic response. Clinicians will be provided with strategies to educate their patients on these therapies and promote self-management to better achieve disease control.

This activity is intended for dermatologists, dermatology nurse practitioners/physician assistants, allergists, and other clinicians involved in the management of atopic dermatitis (AD).

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Recognize the burden of AD on patients and the healthcare system, along with the unmet need for effective treatment options
  • Recognize hallmark signs and symptoms of AD to ensure early recognition and correct diagnosis
  • Use evidence-based tools to determine disease impact and guide treatment decisions
  • Recognize the importance of targeting the underlying pathophysiological drivers of AD
  • Explain how emerging systemic treatments for AD can improve management of the disease and its comorbidities, while considering MOAs, safety and efficacy profiles, indications, and impacts on disease progression

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email:

Diplomates of the American Board of Allergy and Immunology (ABAI) must attest to obtaining 25 hours of Allergy/Immunology-specific CME credits from accredited organizations every year in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified allergists and immunologists in contributing towards this MOC requirement set forth by the ABAI.

Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 CreditsTM annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC.  Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided onsite.

There is no fee associated with this program.

Event staff will be glad to assist you with any special needs. Please email at least 5 days prior to the program.

Jointly provided by the Potomac Center for Medical Education and Rockpointe


This activity has been supported through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.